Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease

被引:31
作者
Weiss, JM
Saltzman, BS
Doherty, JA
Voigt, LF
Chen, C
Beresford, SAA
Hill, DA
Weiss, NS
机构
[1] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98104 USA
[2] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA
[4] Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA
关键词
endometrial neoplasms; neoplasm invasiveness;
D O I
10.1093/aje/kwj152
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
There is a wide range of aggressiveness of endometrial tumors, some being indolent and easily treated while others metastasize and prove fatal. The authors used data from three population-based, case-control studies to determine if etiologic factors differ for aggressive disease. Interview data were obtained from 1,304 female residents of western Washington State who were 45-74 years of age and diagnosed with endometrial cancer during 1985-1991, 1994-1995, and 1997-1999 and from 1,779 controls who were of similar ages and selected primarily by random digit dialing. As a means of gauging aggressiveness, tumor characteristics were abstracted from the population-based cancer registry that serves western Washington State. The risk of endometrial cancer among long-term users (>= 8 years) of unopposed estrogens was particularly high for the least aggressive tumors (odds ratio = 18.6, 95% confidence interval: 12.2, 28.6) but was elevated for moderate and highly aggressive tumors as well (odds ratios = 6.6 and 7.1, respectively). Women who were obese, had a history of diabetes, and had fewer than two children were also at increased risk, regardless of tumor aggressiveness, while oral contraceptive users were at decreased risk of only relatively more aggressive disease. In general, a woman's risk of endometrial cancer appears to be influenced by similar risk factors regardless of disease severity.
引用
收藏
页码:56 / 62
页数:7
相关论文
共 50 条
[1]  
Abeler VM, 1996, CANCER, V78, P1740, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1740::AID-CNCR14>3.0.CO
[2]  
2-Y
[3]   SEROUS PAPILLARY CARCINOMA OF THE ENDOMETRIUM - A HISTOPATHOLOGICAL STUDY OF 22 CASES [J].
ABELER, VM ;
KJORSTAD, KE .
GYNECOLOGIC ONCOLOGY, 1990, 39 (03) :266-271
[4]   The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma [J].
Alektiar, KM ;
Mckee, A ;
Lin, O ;
Venkatraman, E ;
Zelefsky, MJ ;
Mychalczak, BR ;
Mckee, B ;
Hoskins, WJ ;
Barakat, RR .
CANCER, 2002, 95 (02) :316-321
[5]   ENDOMETRIAL CANCER AND ESTROGEN USE - REPORT OF A LARGE CASE-CONTROL STUDY [J].
ANTUNES, CMF ;
STOLLEY, PD ;
ROSENSHEIN, NB ;
DAVIES, JL ;
TONASCIA, JA ;
BROWN, C ;
BURNETT, L ;
RUTLEDGE, A ;
POKEMPNER, M ;
GARCIA, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (01) :9-13
[6]   Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO Stage 1a and 1b endometrial adenocarcinoma: Treatment implications [J].
Aquino-Parsons, C ;
Lim, P ;
Wong, F ;
Mildenberger, M .
GYNECOLOGIC ONCOLOGY, 1998, 71 (01) :83-86
[7]  
Beral Valerie, 2003, Lancet, V362, P419, DOI 10.1016/S0140-6736(03)14065-2
[8]   Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J].
Beresford, SAA ;
Weiss, NS ;
Voigt, LF ;
McKnight, B .
LANCET, 1997, 349 (9050) :458-461
[9]   PICTORIALLY ASSISTED RECALL OF PAST HORMONE USE IN CASE-CONTROL STUDIES [J].
BERESFORD, SAA ;
COKER, AL .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1989, 130 (01) :202-205
[10]  
BRINTON LA, 1993, OBSTET GYNECOL, V81, P265